www.bestgenerics.net
- US Toll free:
- Regular US:
- UK:
- Categories list
-
- Alcoholism
- Alzheimer's And Parkinson's
- Analgesics
- Anti-inflammatories
- Antiallergic
- Antibiotics
- Anticonvulsants
- Antidepressants
- Antifungals
- Antiparasitic
- Antivirals
- Arthritis
- Asthma
- Birth Control
- Cancer
- Cardiovascular Diseases
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Care
- Gastrointestinal Tract
- HIV
- Hypertension
- Men's Health
- Mental Disorders
- Migraine
- Muscle Relaxants
- Neurological Disorders
- Obesity
- Osteoporosis
- Respiratory Tract
- Skin Care
- Surgery
- Urinary Tract
- Women's Health
Choose Your language:
- Testimonials
-
Thank-you for your service, everything has arrived without any hiccups
Read more »
-
- In Early, Aggressive RA, Combo Initially Better Than MTX - Medscape
- In Early, Aggressive RA, Combo Initially Better Than MTXMedscapeTwo-year data reported by the TEAR investigators online April 16 in Arthritis & Rheumatism indicate that the less expensive triple DMARD regimen (methotrexate [MTX]/sulfasalazine/hydroxychloroquine) is generally as effective as etanercept/MTX and that
- Pfizer's Arthritis Pill Gets Nod from FDA Panel - MedPage Today
- Pfizer's Arthritis Pill Gets Nod from FDA PanelMedPage TodayEven some who voted in favor expressed concerns about the possibility that tofacitinib could be used after failure of a single drug such as sulfasalazine or hydroxychloroquine, suggesting that the indication be limited to use after failure of
- IL-17 Blocker Promising for Spondylitis - MedPage Today
- IL-17 Blocker Promising for SpondylitisMedPage TodayThey were allowed to continue on stable doses of other medications such as methotrexate, sulfasalazine, and prednisone
- Arthritis Pill Gets Nod from FDA Panel - Everyday Health
- Arthritis Pill Gets Nod from FDA PanelEveryday HealthEven some who voted in favor expressed concerns about the possibility that tofacitinib could be used after failure of a single drug such as sulfasalazine or hydroxychloroquine, suggesting that the indication be limited to use after failure of
- Takeda's vedolizumab meets primary endpoints in Ph III Crohn's disease study - The Pharma Letter
- Takeda's vedolizumab meets primary endpoints in Ph III Crohn's disease studyThe Pharma LetterUlcerative colitis can be treated with a number of medications including aminosalicylates such as sulfasalazine, corticosteroids such as prednisone, immunosuppressive medications such as azathioprine, and biological agents such as infliximab,
 |
Subscribe to the News |
|---|
